Amgen

The impact of discoid lupus erythematosus (DLE) can go far beyond the skin.    DLE can cause inflamed lesions that can lead to permanent scarring and affect daily life. Yet treatment options remain limited.    By centering patient perspectives and collaborating with organizations like the Lupus Foundation of America, Inc., we can advance scientific knowledge, research and care together.    Go deeper into the impact of DLE and how Amgen is advancing our understanding of the condition and its underlying science: https://lnkd.in/eWBdRjV4   #DLE #LupusAwareness  

What does durable disease control mean for those living with generalized myasthenia gravis (gMG)? Because gMG can be unpredictable, everyday activities, such as walking, talking, or swallowing, can become difficult. As emerging gMG research is presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, it’s equally important to keep patients’ day-to-day experiences at the center of the conversation. Amgen’s Kristina Patterson shares why durable disease control matters. #AANEMinOrlando

Biosimilars have the potential to save the U.S. healthcare system $180B by the end of 2027, but bringing a biosimilar to patients not an easy journey. The process requires years of scientific development, significant investment, specialized manufacturing and highly skilled jobs. It’s why policy decisions made today can help shape the biosimilar marketplace years from now. Follow the journey from investment decisions through launch and beyond. 

Cardiovascular disease remains the leading cause of death worldwide, making it more urgent than ever to understand the factors impacting heart health.    High LDL (“bad”) cholesterol is one of the most well-established, modifiable factors for cardiovascular disease. Managing LDL-C is especially important when conditions like diabetes or obesity are also present. This #WorldHeartDay, let’s remember that every conversation about atherosclerotic cardiovascular risk in patients with high “bad" cholesterol should start with LDL-C. 

We're advancing patient-centered approaches to obesity care and research that support long-term management. Stop by booth B.01 and swipe to see what we’ll be talking about. ➡️ #EASD2026

A serious diagnosis is only one part of a person’s story. The rest of the story is shaped by moments, milestones and memories. Brooke and her family share their story with our Chief Medical Officer, Paul Burton MD PhD FRCP. From treatment for B-cell acute lymphoblastic leukemia to meaningful milestones, including high school graduation and the start of college, Brooke’s story is a powerful reminder of why we pursue breakthrough science: to help create more moments that matter for patients and the people who love them. Watch the full story here: https://amgen.ly/4iN4auc

The number of prostate cancer cases is projected to surpass those of breast cancer in the U.S. this year, according to the American Cancer Society. Meet one man working to change what happens next. Keith Crawford MD, Ph.D, Director of Clinical Trials and Patient Education at Prostate Health Education Network (PHEN), knows exactly why men go quiet: they're not taught to talk about what's wrong with their bodies. Keith’s answer: get up, decide to fight, use every tool available.    This Prostate Cancer Awareness Month, Amgen is proud to support organizations like PHEN that are helping educate and empower people affected by prostate cancer. As we continue advancing prostate cancer research, we remain committed to supporting the community and contributing to progress in prostate cancer care.    Hear why Keith believes every man should have the tools to advocate for his health.

Progress in obesity care begins by listening.  At Amgen’s 2026 Obesity Symposium, 12 leaders across advocacy, clinical care and business came together to explore the barriers, unmet needs and the shared opportunity to advance a more compassionate, person-centered approach for people living with obesity and related conditions.  Take a look at the highlights and stay tuned for more! 

Colorectal cancer isn't on most young adults' radar, but it should be.  Today, 1 in 5 people diagnosed with colorectal cancer in the U.S. is under age 55, nearly double the rate in the 1990s. Anastasia is one of them. At 26, she’s using her voice to help other young people know the signs and seek support.    At Amgen, we've been driving progress in colorectal cancer care for two decades. Stories like Anastasia's are why we keep going.    Read more about her journey: https://amgen.ly/4yi1nOG

Researchers are continuing to explore how shared immunological themes across inflammatory diseases could deepen our understanding of the biology of inflammation. Looking across diseases and bringing different specialties together may help reveal connections that are harder to see in isolation. Jean Pierre Llanos Ackert, MD, ATSF, Amgen’s Global Medical Inflammation Therapeutic Area lead shares his point of view on what we can learn when specialists compare notes and ask bigger questions about the science connecting inflammatory diseases. Read his full perspective: https://amgen.ly/3VKzWyg